

Germany: Ifo stuck between vaccine and new lockdown

Don't get carried away by the stronger Ifo index. Due to the new lockdown measures, the German economy has entered a period of hibernation at the turn of the year and it will take until the second quarter before a significant rebound materialises



Source: Shutterstock

Germany's most prominent leading indicator rebounded in December. The Ifo index increased to 92.1, from 90.9 in November, but still remains below the 92.5 in October. While the current assessment component improved to 91.3, from 90.0, the highest level since March, improved expectations remain clearly below summer levels.

Interpreting today's Ifo index is not easy as it was possible to fill in the survey before and after the announcement of the country's strict lockdown last Sunday. Therefore, the higher Ifo reading probably tells us more about the news and the rolling out of the vaccine, rather than the new lockdown measures.

It will get worse before getting better

The picture of the German economy at the end of a very exceptional and unprecedented year is complicated, to say the least. Three factors are currently shaping the short-term outlook: i) after two consecutive quarters of negative impact on growth from both the construction sector and inventories, a rebound would normally be in the making. The last time the construction sector contracted three quarters in a row was 2004. ii) the manufacturing sector had a strong start to the fourth quarter, confidence remains high and order books are filled, so a contraction of the entire industry is not yet obvious. iii) the gradual tightening of restrictions up to the latest de facto shutdown of the country have led to a continuing weakening of activity in the services sector and lately also in consumption.

Expect the entire economy to go into hibernation at the turn of the year. A double dip in the fourth quarter looks inevitable, even though the strong performance of the manufacturing and construction sector up to now should make this contraction a very mild one. Looking ahead, however, it currently seems reasonable to expect an extension of the lockdown measures beyond 10 January. Given the sharp increases in new infections, an even tighter lockdown in the coming weeks can no longer be excluded. Add to this the very gradual rolling out of the vaccine and the first quarter will also be very weak. In fact, at the current juncture, a technical recession (i.e. two consecutive quarters of contraction) is also in the cards.

Before drowning in despair, the silver linings are visible. By springtime, the rolling out of the vaccine should have gained momentum and the better weather should help to significantly ease the restrictive measures and hence support the economy. Plus, the ongoing fiscal and monetary stimulus as well as an improving global economy should support and benefit the German economy throughout 2021. Hang in there. Merry Christmas.

Author

Carsten Brzeski

Global Head of Macro

carsten.brzeski@ing.de

Disclaimer

This publication has been prepared by the Economic and Financial Analysis Division of ING Bank N.V. ("ING") solely for information purposes without regard to any particular user's investment objectives, financial situation, or means. *ING forms part of ING Group (being for this purpose ING Group N.V. and its subsidiary and affiliated companies).* The information in the publication is not an investment recommendation and it is not investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument. Reasonable care has been taken to ensure that this publication is not untrue or misleading when published, but ING does not represent that it is accurate or complete. ING does not accept any liability for any direct, indirect or consequential loss arising from any use of this publication. Unless otherwise stated, any views, forecasts, or estimates are solely those of the author(s), as of the date of the publication and are subject to change without notice.

The distribution of this publication may be restricted by law or regulation in different jurisdictions and persons into whose possession this publication comes should inform themselves about, and observe, such restrictions.

Copyright and database rights protection exists in this report and it may not be reproduced, distributed or published by any person for any purpose without the prior express consent of ING. All rights are reserved. ING Bank N.V. is authorised by the Dutch Central Bank and supervised by the European Central Bank (ECB), the Dutch Central Bank (DNB) and the Dutch Authority for the Financial Markets (AFM). ING Bank N.V. is incorporated in the Netherlands (Trade Register no. 33031431 Amsterdam). In the United Kingdom this information is approved and/or communicated by ING Bank N.V., London Branch. ING Bank N.V., London Branch is authorised by

the Prudential Regulation Authority and is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. ING Bank N.V., London branch is registered in England (Registration number BR000341) at 8-10 Moorgate, London EC2 6DA. For US Investors: Any person wishing to discuss this report or effect transactions in any security discussed herein should contact ING Financial Markets LLC, which is a member of the NYSE, FINRA and SIPC and part of ING, and which has accepted responsibility for the distribution of this report in the United States under applicable requirements.

Additional information is available on request. For more information about ING Group, please visit <http://www.ing.com>.